The reduction in the ATM cap is a modest positive signal of capital discipline, but the remaining ~$74.9M of potential issuance still creates a large dilution overhang (~39% of market cap). Monitor actual ATM usage in future filings — if the company draws down significantly, it will pressure the stock.
Price Chart
Executive Summary
Kazia Therapeutics filed a 424B5 prospectus supplement reducing the maximum aggregate offering price of ADSs available under its existing ATM facility with Leerink Partners from $100M to $80M. As of the filing date, the company had sold 510,000 ADSs for approximately $5.1M under the prior shelf. The reduction of available capacity is a modest positive signal, suggesting management is tempering the potential dilution overhang, but the remaining $74.9M of potential future issuance still represents a substantial overhang relative to the $193M market cap. The filing is a routine administrative amendment to an existing at-the-market offering program, not a new dilutive event.
Key Facts
- Maximum aggregate offering price reduced from $100M to $80M under the existing ATM facility with Leerink Partners.
- As of the filing date, 510,000 ADSs had been sold for aggregate proceeds of approximately $5,106,516 under the prior shelf.
- Remaining capacity under the amended facility is up to ~$74.9M (the $80M cap less ~$5.1M already sold).
- The ADSs trade on Nasdaq under KZIA; closing price on August 27, 2026 was $16.90 per ADS.
- The company is a foreign private issuer (Australian-domiciled) with a market cap of ~$193M.
Financial Impact
Reduction of maximum offering size from $100M to $80M — a $20M decrease in potential future dilution. Remaining capacity of ~$74.9M represents ~39% of current market cap ($193M).
Risk Factors
- Remaining ~$74.9M ATM capacity could be drawn at any time, diluting existing shareholders.
- The company has filed 24 offering/registration documents in the last 24 months, indicating a pattern of frequent capital access.
- As a pre-commercial biotech, the company likely needs ongoing capital to fund operations and clinical trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001213900-26-094600 |
| Document: 0001213900-26-094600-index-headers.html | 0001213900-26-094600 |
| Document: 0001213900-26-094600-index.html | 0001213900-26-094600 |
| Document: 0001213900-26-094600.txt | 0001213900-26-094600 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 24d ago | SC 13G/A | $9.27 | awaiting T+20 | — | $7.87 (−15.10%) |
Sep 22, 2026 4w ago | 6-K | $10.92 $7.88 | ▼ −27.84% | ▼ −27.28% | $7.87 (−27.93%) |
Sep 1, 2026 7w ago | 6-K | $12.61 $9.60 | ▼ −23.91% | ▼ −23.58% | $7.87 (−37.59%) |
Aug 31, 2026 8w ago | Press Release | $12.63 $9.60 | ▲ +24.03% | ▲ +24.35% | $7.87 (+37.69%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▼ −29.19% | ▼ −29.01% | $7.87 (−42.85%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $7.87 (+42.85%) |
Aug 31, 2026 8w ago | 424B5 | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $7.87 (+42.85%) |
Aug 28, 2026 8w ago | 6-K / 424B5 | $13.58 $9.60 | ▲ +29.31% | ▲ +29.57% | $7.87 (+42.05%) |
Aug 28, 2026 8w ago | 424B5 | $13.58 $9.60 | ▼ −29.31% | ▼ −29.57% | $7.87 (−42.05%) |
Jul 28, 2026 12w ago | 6-K | $12.69 $13.79 | ▲ +8.67% | ▲ +5.29% | $7.87 (−37.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers